Soleno Therapeutics, Inc. SLNO
Set alert
53.01 USD 0.00 0.00%
At close · May 15
52.99 -0.02 -0.04%
After hours · May 15, 4:00 PM ET
52.98 Day range 53.01
52-week range unavailable
- YTD
- +14.49%
- 1 year
- -29.33%
- Open
- 52.99
- Prev close
- 53.01
- Mkt cap
- 2.76B
- Vol
- 4.97M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 52.98
- High
- 53.01
- Beta
- -2.22
- Inst. own
- 111.53%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
Analyst view
Price target (mean) —
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.9338 | 0.78 – 1.26 | -0.09 | +1137.5% | 111.80M | +242.4% | 8 |
| Current quarter | 0.68 | 0.20 – 0.93 | -0.95 | +171.6% | 93.75M | 0.0% | 12 |
| Current quarter | 0.0575 | -0.28 – 0.37 | -1.83 | +103.1% | 48.09M | 0.0% | 12 |
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 25.14M | 0.0% | 0 |
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current quarter | -0.63 | -0.67 – -0.56 | -0.95 | +33.7% | 0 | 0.0% | 8 |
| Current quarter | -0.60 | -0.66 – -0.45 | -0.81 | +25.9% | 0 | 0.0% | 6 |
| Current quarter | -0.37 | -0.66 – -0.27 | -0.88 | +58.0% | 0 | 0.0% | 6 |
| Current quarter | -0.58 | -0.62 – -0.52 | -0.76 | +23.7% | 0 | 0.0% | 3 |
| Current quarter | -0.83 | -0.90 – -0.70 | -0.90 | +7.8% | 0 | 0.0% | 3 |
| Current quarter | -0.72 | -0.74 – -0.71 | -1.08 | +33.3% | 0 | 0.0% | 2 |
| Current quarter | -1.05 | -1.05 – -1.05 | -1.50 | +30.0% | 0 | 0.0% | 1 |
| Current quarter | -0.06 | -0.07 – -0.05 | -0.14 | +57.1% | 0 | 0.0% | 2 |
| Current quarter | -0.07 | -0.09 – -0.05 | -0.11 | +36.4% | 0 | 0.0% | 2 |
| Current quarter | -0.11 | -0.11 – -0.11 | -0.11 | 0.0% | 0 | 0.0% | 3 |
| Current quarter | -0.11 | -0.14 – -0.08 | -0.16 | +31.2% | 0 | 0.0% | 3 |
| Current quarter | -0.08 | -0.10 – -0.04 | -0.13 | +38.5% | 0 | 0.0% | 3 |
| Current quarter | -0.09 | -0.11 – -0.04 | 0.03 | -400.0% | 0 | 0.0% | 3 |
| Current quarter | -0.20 | -0.21 – -0.20 | -0.31 | +35.5% | 0 | 0.0% | 2 |
| Current quarter | -0.20 | -0.22 – -0.18 | -0.22 | +9.1% | 0 | 0.0% | 3 |
| Current quarter | -0.16 | -0.17 – -0.15 | -0.13 | -23.1% | 0 | 0.0% | 2 |
| Current quarter | -0.17 | -0.19 – -0.16 | -0.38 | +55.3% | 0 | 0.0% | 2 |
| Current quarter | -0.29 | -0.29 – -0.29 | -0.53 | +45.3% | 0 | 0.0% | 1 |
| Current quarter | 0.00 | 0.00 – 0.00 | -0.30 | +26.7% | 0 | 0.0% | 0 |
| Current quarter | 0.00 | 0.00 – 0.00 | -0.55 | 0.0% | 0 | +884.9% | 0 |
| Next quarter | 1.06 | 0.78 – 1.55 | 0.47 | +125.5% | 122.86M | +86.1% | 8 |
| Next quarter | -0.19 | -0.19 – -0.19 | -0.30 | +36.7% | 70.00K | +6900.0% | 1 |
| Current year | 3.89 | 2.69 – 5.55 | 0.39 | +897.8% | 464.33M | +143.9% | 8 |
| Current year | 0.2931 | -0.12 – 0.85 | -4.38 | +106.7% | 187.28M | 0.0% | 13 |
| Current year | 0.00 | 0.00 – 0.00 | -2.36 | -77.3% | 0 | 0.0% | 0 |
| Current year | -2.47 | -2.95 – -1.76 | -2.87 | +13.9% | 0 | 0.0% | 6 |
| Current year | -3.43 | -3.43 – -3.43 | -5.85 | +41.4% | 0 | 0.0% | 1 |
| Current year | -0.43 | -0.44 – -0.43 | -0.39 | -10.3% | 0 | 0.0% | 2 |
| Current year | -0.45 | -0.47 – -0.43 | -0.90 | +50.0% | 0 | 0.0% | 3 |
| Current year | -0.67 | -0.68 – -0.65 | -0.73 | +8.2% | 0 | 0.0% | 3 |
| Current year | -0.98 | -0.98 – -0.98 | -1.53 | +35.9% | 0 | 0.0% | 1 |
| Current year | -1.19 | -1.19 – -1.19 | -5.00 | +76.2% | 270.00K | -81.4% | 1 |
| Next year | 6.06 | 3.61 – 9.92 | 3.89 | +55.6% | 670.46M | +44.4% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 7, 2026 | TD Cowen | Downgrade | Buy | Hold |
| Apr 7, 2026 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Mar 18, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Jan 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Outperform |
| Nov 5, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 27, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Aug 20, 2025 | Wells Fargo | Initiated | — | Overweight |
| Aug 18, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 7, 2025 | Guggenheim | Maintained | Buy | Buy |
| Aug 7, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Jul 11, 2025 | Baird | Maintained | Outperform | Outperform |
| May 8, 2025 | Guggenheim | Maintained | Buy | Buy |
| May 8, 2025 | Baird | Maintained | Outperform | Outperform |
| Apr 24, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 15, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 31, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 28, 2025 | Stifel | Maintained | Buy | Buy |
| Mar 28, 2025 | Guggenheim | Maintained | Buy | Buy |
| Mar 27, 2025 | Laidlaw & Co. | Maintained | Buy | Buy |
| Mar 27, 2025 | Baird | Maintained | Outperform | Outperform |
| Mar 27, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Mar 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
